Gensight Biologics
Clinical trials sponsored by Gensight Biologics, explained in plain language.
-
Gene therapy and High-Tech glasses aim to restore sight in blinding eye disease
Disease control OngoingThis early-stage study is testing the safety of a new gene therapy called GS030 for people with retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive a single injection into the eye and then use special stimulating glasses. The main goal is to …
Phase: PHASE1, PHASE2 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Experimental gene therapy offered to single patient with rare blinding condition
Disease control NO_LONGER_AVAILABLEThis was an expanded access program that provided an experimental gene therapy called GS010 to one patient with Leber hereditary optic neuropathy, a rare genetic condition that causes vision loss. The therapy involved injections into both eyes and aimed to control the disease by …
Sponsor: GenSight Biologics • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC